evidence: The most afflicted areas, with prevalence rates over 1%, are two provinces in the south-eastern part of the People’s Republic of China (Guangdong and Guangxi) and two in the north-eastern part (Heilongjiang and Jilin) (Table 1 and Fig. 1c) [51]. Compared to 2014–2015, the national control plan for 2016–2020 aims to decrease the prevalence in all major endemic provinces by 30% in 2020 through implementation of an integrating control strategy, consisting of chemotherapy, IEC, and improved sanitation [41].